William Blair analyst Myles Minter reiterated an Outperform rating on Silence Therapeutics (NASDAQ: SLN)The analyst commented, "We continue to view ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE